Eva Niv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Eva Niv has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adi Talan Asher
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel
1 shared publication - Arad Dotan
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel
1 shared publication - Ayal Hirsch
IBD Unit, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Israel; Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
1 shared publication - Liat Deutsch
Tel Aviv Sourasky Medical Center
1 shared publication - Moshe Leshno
Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
1 shared publication - Nitsan Maharshak
IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
1 shared publication
Latest Publications
- Open Access
- 9 October 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (11) , 4178-4186
Pro-motility Preparation Protocol May Reduce the Rates of Failed Patency Capsule Among Patients with Crohn’s Disease in Clinical Remission
Background Patency capsule (PC) ingestion is commonly used to minimize capsule retention in high-risk patients with Crohn’s disease (CD). However, false-positive rates remain high, precluding the use of video capsule endoscopy (VCE). We aimed to compare the efficacy of two preparation protocols in reducing failed PC rates in patients with CD. Methods This bi-center retrospective case–control study included adult patients with small-bowel CD in clinical remission who underwent PC ingestion. The pro-motility group followed a low-residue diet, then a clear fluid diet, and took bisacodyl after ingestion, while the control group followed only a clear fluid diet. The primary outcome was failed PC, defined as the absence of PC excretion or presence on abdominal X-ray at 30 h post-ingestion. Multivariable logistic regression was used to identify predictors of failed PC. Results Among 273 patients (83 in the pro-motility group, 190 controls), the pro-motility group was older (median 36 [27–48] vs. 31 [24–43], p = 0.012) and had a lower rate of B2/3 disease phenotype (32.5 vs. 53.1%, p = 0.002) compared to controls. The pro-motility group also had a lower failed PC rate (12.0 vs. 24.7%, p = 0.023). Longer disease duration (adjusted odds ratio (AOR) 1.053, 95% confidence interval (CI) 1.016–1.091, p = 0.005) increased the odds of failed PC, while the pro-motility protocol was protective (AOR 0.438, 95% CI 0.200–0.956, p = 0.038), outweighing the influence of B2/3 disease phenotype (AOR 1.743, 95% CI 0.912–3.332, p = 0.093). Conclusions The pro-motility preparation protocol could substantially improve the success rates of the small-bowel patency test in patients with CD undergoing PC ingestion, potentially reducing the risk of capsule retention and associated complications.
- 9 October 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (11) , 4178-4186
Open AccessPro-motility Preparation Protocol May Reduce the Rates of Failed Patency Capsule Among Patients with Crohn’s Disease in Clinical Remission
Background Patency capsule (PC) ingestion is commonly used to minimize capsule retention in high-risk patients with Crohn’s disease (CD). However, false-positive rates remain high, precluding the use of video capsule endoscopy (VCE). We aimed to compare the efficacy of two preparation protocols in reducing failed PC rates in patients with CD. Methods This bi-center retrospective case–control study included adult patients with small-bowel CD in clinical remission who underwent PC ingestion. The pro-motility group followed a low-residue diet, then a clear fluid diet, and took bisacodyl after ingestion, while the control group followed only a clear fluid diet. The primary outcome was failed PC, defined as the absence of PC excretion or presence on abdominal X-ray at 30 h post-ingestion. Multivariable logistic regression was used to identify predictors of failed PC. Results Among 273 patients (83 in the pro-motility group, 190 controls), the pro-motility group was older (median 36 [27–48] vs. 31 [24–43], p = 0.012) and had a lower rate of B2/3 disease phenotype (32.5 vs. 53.1%, p = 0.002) compared to controls. The pro-motility group also had a lower failed PC rate (12.0 vs. 24.7%, p = 0.023). Longer disease duration (adjusted odds ratio (AOR) 1.053, 95% confidence interval (CI) 1.016–1.091, p = 0.005) increased the odds of failed PC, while the pro-motility protocol was protective (AOR 0.438, 95% CI 0.200–0.956, p = 0.038), outweighing the influence of B2/3 disease phenotype (AOR 1.743, 95% CI 0.912–3.332, p = 0.093). Conclusions The pro-motility preparation protocol could substantially improve the success rates of the small-bowel patency test in patients with CD undergoing PC ingestion, potentially reducing the risk of capsule retention and associated complications.